文献速递泌尿男性生殖肿瘤

DaBlaCa-13研究:丝裂霉素短期强化化学消融治疗非肌层浸润性膀胱癌的肿瘤学结局:随机对照试验的主要结局

DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2022-10-12

在丹麦两个泌尿外科进行的随机对照试验纳入120例复发性Ta低级别或高级别非肌层浸润性膀胱癌患者,比较短期强化丝裂霉素化学消融与标准手术治疗的疗效。干预组需接受手术操作的患者比例为71%(95%CI 57-81),显著低于对照组的100%(95%CI 94-100),P<.001。两组12个月无复发生存率分别为36%(95%CI 24-50)和43%(95%CI 30-56),差异无统计学意义(P=.5)。

要点

  • 复发性非肌层浸润性膀胱癌患者接受短期强化丝裂霉素化学消融后,需接受手术操作的比例为71%,低于标准手术组的100%。
  • 干预组12个月无复发生存率为36%,对照组为43%,两组差异无统计学意义(P=.5)。
  • 短期强化化学消融可减少复发时所需的手术操作,且不损害长期肿瘤学安全性。

核心结论

  • 短期强化化学消融是复发性非肌层浸润性膀胱癌的有效治疗策略,可减少所需手术操作次数,且不损害长期肿瘤学安全性。

研究设计与样本

  • 随机对照试验,2018年1月至2021年8月在丹麦两个泌尿外科进行,共纳入120例有Ta低级别或高级别非肌层浸润性膀胱癌病史的复发患者。
  • 干预组接受膀胱内丝裂霉素(40 mg/40 mL)每周3次共2周,仅在反应不完全时行经尿道膀胱肿瘤电切术(TURBT)或诊室活检。
  • 对照组接受TURBT或诊室活检,并接受6次每周辅助灌注。
  • 主要结局为入组后2年内接受手术操作的患者数,采用卡方检验比较;无复发生存采用Kaplan-Meier法分析。

主要发现

  • 干预组需要接受手术操作的患者比例为71%(95%CI 57-81),对照组为100%(95%CI 94-100),P<.001。
  • 干预组12个月无复发生存率为36%(95%CI 24-50),对照组为43%(95%CI 30-56),P=.5。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to assess long-term follow-up after chemoresection with mitomycin (MMC), a nonsurgical treatment modality for recurrent nonmuscle invasive bladder cancer (NMIBC). At the time of recurrence, chemoresection has previously been shown to reduce the number of patients requiring a procedure (transurethral resection of bladder tumors [TURBT] or office biopsy) by more than 50%. This study investigated the number of patients requiring a procedure during initial treatment and 2-year follow-up in patients treated with short-term, intensive chemoresection with MMC compared with patients undergoing standard surgical treatment of recurrent NMIBC. METHODS: A randomized, controlled trial was conducted in two urological departments in Denmark from January 2018 to August 2021. In total, 120 patients with a history of Ta low- or high-grade NMIBC were included upon recurrence. The intervention group received intravesical MMC (40 mg/40 mL) three times a week for 2 weeks and TURBT or office biopsy only if the response was incomplete. The control group received TURBT or office biopsy and 6 weekly adjuvant instillations. The primary outcome was the number of patients undergoing a procedure within 2 years from inclusion, which was compared between groups using the chi-squared test. Recurrence-free survival was analyzed using the Kaplan-Meier method. RESULTS: Significantly fewer patients were in need of a procedure in the intervention group than in the control group: 71% (95% CI, 57 to 81) and 100% (95% CI, 94 to 100), P < .001. The 12-month recurrence-free survival was 36% (95% CI, 24 to 50) and 43% (95% CI, 30 to 56) in the intervention and control groups, respectively (P = .5). CONCLUSION: Short-term intensive chemoresection is an effective treatment strategy for recurrent NMIBC that leads to a reduced number of required procedures without compromising long-term oncological safety.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Lindgren MS, Hansen E, Azawi N, et al. DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol. 2022. PMID: 36223555. doi:10.1200/JCO.22.00470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。